Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $61,934.58 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,629 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Friday, January 24th, Jeffrey Dierks sold 13,125 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.31, for a total transaction of $489,693.75.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $39.54 on Friday. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm’s 50-day moving average price is $35.20 and its two-hundred day moving average price is $35.22. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61. The stock has a market capitalization of $2.26 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the business earned $0.63 earnings per share. As a group, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HRMY. Pacer Advisors Inc. grew its position in Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after buying an additional 351,582 shares during the last quarter. Marshall Wace LLP grew its position in Harmony Biosciences by 145.4% in the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after buying an additional 181,092 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after buying an additional 140,690 shares during the last quarter. HealthInvest Partners AB grew its position in Harmony Biosciences by 335.2% in the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after buying an additional 116,975 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Harmony Biosciences by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after purchasing an additional 112,197 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HRMY shares. Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Cantor Fitzgerald increased their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, Mizuho increased their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences has an average rating of “Buy” and a consensus price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.